Elanco Animal Health Incorporated $ELAN Shares Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 55.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,611,977 shares of the company’s stock after acquiring an additional 1,645,331 shares during the quarter. Artemis Investment Management LLP’s holdings in Elanco Animal Health were worth $103,262,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Anchor Investment Management LLC purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at about $29,000. Integrated Wealth Concepts LLC purchased a new stake in Elanco Animal Health during the second quarter worth approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health in the second quarter valued at approximately $38,000. Bessemer Group Inc. boosted its holdings in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after purchasing an additional 525 shares in the last quarter. Finally, Signature Equity Partners LLC increased its stake in Elanco Animal Health by 4,289.1% in the first quarter. Signature Equity Partners LLC now owns 6,057 shares of the company’s stock valued at $145,000 after purchasing an additional 5,919 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the acquisition, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul Herendeen purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares in the company, valued at $2,644,748.16. The trade was a 9.83% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 63,198 shares of company stock worth $1,473,109 in the last 90 days. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded up $0.04 during midday trading on Thursday, hitting $22.40. 812,932 shares of the stock were exchanged, compared to its average volume of 5,639,358. Elanco Animal Health Incorporated has a twelve month low of $19.40 and a twelve month high of $27.98. The stock has a market cap of $11.19 billion, a P/E ratio of -54.76, a PEG ratio of 1.60 and a beta of 1.70. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The company has a 50 day moving average price of $23.55 and a 200-day moving average price of $23.65.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the business earned $0.26 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen raised their price target on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. UBS Group upped their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Morgan Stanley increased their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $29.70.

Elanco Animal Health Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.